RAPT Therapeutics, Inc.RAPTNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

14 analysts·Moderate coverage

29%

Rating Distribution

Strong Buy

00%

Buy

429%

Hold

1071%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Current price is 9% above analyst consensus — modest downside expected.

Bear Case

$9.00

-84%

Consensus

$52.71

-9%

Bull Case

$70.00

+21%

Price Range14 analysts

Low

Consensus

High

$9.00

$70.00

Current Target

Current Price

$57.68

Above Target

$4.97

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-3.24(5 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev-92.10%

EPS—

FY2028

Rev+10292.93%

EPS—

FY2029

Rev-78.32%

EPS—

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:-3.4%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 21, 2026Barclays

Rapt Therapeutics downgraded to Equal Weight from Overweight at Barclays

Target:$58.00

+0.7%from $57.59

Jan 21, 2026Leerink Partners

Leerink Partners Downgrades Rapt Therapeutics (RAPT) to Market Perform

Target:$58.00

+0.7%from $57.57

Jan 20, 2026Wells Fargo

Rapt Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo

Target:$58.00

+0.9%from $57.50

Jan 20, 2026H.C. Wainwright

Rapt Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Target:$58.00

+0.8%from $57.51

Jan 20, 2026Piper Sandler

Rapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Target:$58.00

+0.8%from $57.52

Jan 9, 2026Piper Sandler

Rapt Therapeutics initiated with an Overweight at Piper Sandler

Target:$95.00

+204.5%from $31.20

Nov 3, 2025Wells Fargo

Rapt Therapeutics price target raised to $72 from $48 at Wells Fargo

Target:$72.00

+138.3%from $30.21

Oct 27, 2025H.C. Wainwright

Rapt Therapeutics price target raised to $72 from $27 at H.C. Wainwright

Target:$72.00

+139.8%from $30.03

Oct 27, 2025Guggenheim

Rapt Therapeutics initiated with a Buy at Guggenheim

Target:$70.00

+137.0%from $29.53

Oct 13, 2025Barclays

Rapt Therapeutics initiated with an Overweight at Barclays

Target:$35.00

+30.6%from $26.79

Sep 26, 2025Leerink Partners

Rapt Therapeutics upgraded to Outperform from Market Perform at Leerink

Target:$37.00

+57.4%from $23.50

Aug 12, 2025UBS

Rapt Therapeutics price target raised to $9 from $8 at UBS

Target:$9.00

-5.0%from $9.47

Nov 12, 2024Leerink Partners

Leerink Partners Reiterates Market Perform Rating on Rapt Therapeutics (RAPT)

Target:$2.00

+14.9%from $1.74

Nov 12, 2024Stifel Nicolaus

Stifel Downgrades Rapt Therapeutics (RAPT) to Hold

Target:$2.00

+14.9%from $1.74

Jan 4, 2023Guggenheim

Guggenheim Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $55

Target:$55.00

+177.4%from $19.82

Jan 4, 2023Wells Fargo

Wells Fargo Maintains Overweight on RAPT Therapeutics, Lowers Price Target to $48

Target:$48.00

+146.2%from $19.50

Dec 8, 2022Piper Sandler

Rapt Therapeutics price target lowered to $33 from $34 at Piper Sandler

Target:$33.00

+100.2%from $16.48

Dec 1, 2022Goldman Sachs

Goldman Sachs Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $27

Target:$27.00

+52.7%from $17.68

Nov 11, 2022Piper Sandler

Piper Sandler Maintains Overweight on RAPT Therapeutics, Raises Price Target to $34

Target:$34.00

+54.7%from $21.98

Sep 21, 2022Capital One Financial

Capital One starts Rapt with Overweight, sees 100% upside

Target:$48.00

+98.6%from $24.17

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance